1154740-67-6

Basic information

• Product Name: 6-bromo-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazine
• Synonyms: 6-bromo-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazine;6-Bromo-5-chloro-3,4-dihydro-2H-benzo[1,4]oxazine
• CAS NO: 1154740-67-6
• Molecular Formula: C8H7BrClNO
• Molecular Weight: 248.50428
• Mol File: 1154740-67-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 327.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.640±0.06 g/cm3(Predicted)
• PKA: 1.82±0.20(Predicted)
• CAS DataBase Reference: 6-bromo-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazine(1154740-67-6)
• EPA Substance Registry System: 6-bromo-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazine(1154740-67-6)

Safety Data

• Hazardous Substances Data: 1154740-67-6(Hazardous Substances Data)

Upstream product

• 138035-68-4 5-chloro-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 56962-00-6 2-amino-3-chlorophenol 
• 64182-61-2 1-chloro-3-fluoro-2-nitrobenzene 
• 17802-02-7 2-nitro-3-chlorophenol 
• 1154740-66-5 6-bromo-5-chloro-2H-1,4-benzoxazin-3(4H)-one 

Downstream Products

• 1256254-54-2 C₃₀H₃₆N₂O₄ 
• 1256250-76-6 C₂₉H₃₄N₂O₄ 
• 1155264-46-2 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine 
• 1155288-89-3 C₃₁H₃₁ClN₂O₄ 

Relevant articles and documents

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula I wherein a, R1, R2, R3, R4, R5 and R6 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula (I): wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

The present invention relates to compounds of formula (I) wherein c, X, Y, R2, R3, R4 and R6 are as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection